Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Niaspan niacin: Post marketing study data

In the double-blind, placebo-controlled, U.S. ARBITER 2 trial in 167 patients, Niaspan plus statin therapy

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE